Glück Conviction Score™ ⓘ
IMVT
Immunovant, Inc.
Effektiv: Neutral
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
49,5
42 neu, 91 erhöht, -39951K $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 29.17 | +15.2 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 24.34 | +38.1 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 31.55 | EMA50: 29.75 | |
| MACD-Histogramm | Bärisch | 10 % | -0.101 | Bearisch | |
| RSI(14) | Neutral | 10 % | 60.2 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 64.8 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 22.2 | +DI: 29.9 / −DI: 16.3 | |
| Z-Score(60) | Bärisch | 5 % | 1.60 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 90.7 % | Hoch 35.56 / Tief 14.69 | |
| Bollinger(20,2σ) | Neutral | 5 % | 67.8 % | Upper 36.81 / Mid 31.85 / Lower 26.89 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1648 | R²=0.76 / annualisiert +146.4 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | Fromkin Andrew J. | Director | Open Market Sale | -11.483 | 32,64 | -374.805,12 | -4,0% | |
| 2026-05-28 | Fromkin Andrew J. | Director | Open Market Sale | -210.468 | 33,56 | -7.063.306,08 | -76,2% | |
| 2026-05-20 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -1.698 | 32,95 | -55.949,10 | -0,6% | |
| 2026-05-20 | Pande Atul | Director | Open Market Sale | -6.000 | 32,00 | -192.000,00 | -2,1% | |
| 2026-05-20 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -1.168 | 32,15 | -37.551,20 | -0,4% | |
| 2026-05-20 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -249 | 30,41 | -7.572,09 | -0,1% | |
| 2026-05-01 | Susman Robert Graham | Director | Open Market Sale | -2.502 | 27,17 | -67.979,34 | -0,7% | |
| 2026-04-23 | Girao Tiago | Officer, Chief Financial Officer | Open Market Sale | -25.760 | 29,62 | -763.011,20 | -8,2% | |
| 2026-04-23 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -2.754 | 29,62 | -81.573,48 | -0,9% | |
| 2026-04-08 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -8.722 | 24,83 | -216.567,26 | -2,3% | |
| 2026-04-08 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -8.614 | 24,83 | -213.885,62 | -2,3% | |
| 2026-04-08 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1.518 | 24,83 | -37.691,94 | -0,4% | |
| 2026-04-08 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -5.165 | 24,83 | -128.246,95 | -1,4% | |
| 2026-04-02 | Venker Eric | Director, Officer, Chief Executive Officer | Open Market Sale | -1.409 | 24,60 | -34.661,40 | -0,4% | |
| 2026-04-02 | Venker Eric | Director, Officer, Chief Executive Officer | Open Market Sale | -12.820 | 24,04 | -308.192,80 | -3,3% | |
| 2026-03-18 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -2.877 | 24,97 | -71.838,69 | -0,8% | |
| 2026-02-25 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -942 | 28,90 | -27.223,80 | -0,3% | |
| 2026-02-25 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -1.437 | 26,98 | -38.770,26 | -0,4% | |
| 2026-02-25 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -859 | 28,16 | -24.189,44 | -0,3% | |
| 2026-01-21 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1.977 | 26,03 | -51.461,31 | -0,6% | |
| 2026-01-07 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1.148 | 26,51 | -30.433,48 | -0,3% | |
| 2026-01-07 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -55 | 26,92 | -1.480,60 | 0,0% | |
| 2025-12-18 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -8.529 | 26,78 | -228.406,62 | -2,5% | |
| 2025-12-18 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -2.284 | 27,38 | -62.535,92 | -0,7% | |
| 2025-12-12 | Roivant Sciences Ltd. | Director, 10% Owner | Open Market Purchase | 16.666.666 | 21,00 | 349.999.986,00 | +3775,2% | |
| 2025-12-01 | Fromkin Andrew J. | Director | Open Market Sale | -19.351 | 23,14 | -447.782,14 | -4,8% | |
| 2025-12-01 | Hughes Douglas J. | Director | Open Market Sale | -13.091 | 23,14 | -302.925,74 | -3,3% | |
| 2025-12-01 | Hughes Douglas J. | Director | Open Market Sale | -1.909 | 23,96 | -45.739,64 | -0,5% | |
| 2025-12-01 | Fromkin Andrew J. | Director | Open Market Sale | -2.898 | 23,95 | -69.407,10 | -0,7% | |
| 2025-11-20 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -10.251 | 23,54 | -241.308,54 | -2,6% | |
| 2025-11-20 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -2.375 | 23,97 | -56.928,75 | -0,6% | |
| 2025-10-22 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -2.520 | 19,03 | -47.955,60 | -0,5% | |
| 2025-10-22 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -2.595 | 19,03 | -49.382,85 | -0,5% | |
| 2025-10-08 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1.585 | 16,30 | -25.835,50 | -0,3% | |
| 2025-10-08 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -1.272 | 16,30 | -20.733,60 | -0,2% | |
| 2025-07-23 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -2.805 | 18,15 | -50.910,75 | -0,5% | |
| 2025-07-23 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -2.385 | 18,15 | -43.287,75 | -0,5% | |
| 2025-07-09 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1.519 | 17,24 | -26.187,56 | -0,3% | |
| 2025-07-09 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -1.160 | 17,24 | -19.998,40 | -0,2% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 16.947.888 | 16.990.754 | -42.866 | 420.985.547 | Reduziert | -0,3% | |
| Deep Track Capital, LP | 11.526.971 | 11.526.971 | 0 | 286.329.960 | Unverändert | 0,0% | |
| VANGUARD GROUP INC | 7.779.314 | 0 | 7.779.314 | 197.750.162 | Neu | +100,0% | |
| BlackRock, Inc. | 6.574.497 | 6.058.216 | 516.281 | 163.310.512 | Aufgestockt | +8,5% | |
| ARMISTICE CAPITAL, LLC | 5.464.916 | 6.497.155 | -1.032.239 | 135.748.513 | Reduziert | -15,9% | |
| BAKER BROS. ADVISORS LP | 5.457.881 | 5.457.881 | 0 | 135.573.764 | Unverändert | 0,0% | |
| STATE STREET CORP | 4.537.929 | 3.786.926 | 751.003 | 112.722.156 | Aufgestockt | +19,8% | |
| TCG Crossover Management, LLC | 4.457.988 | 1.660.933 | 2.797.055 | 110.736.422 | Aufgestockt | +168,4% | |
| MORGAN STANLEY | 3.876.877 | 4.846.385 | -969.508 | 96.301.649 | Reduziert | -20,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.620.050 | 0 | 3.620.050 | 89.922.042 | Neu | +100,0% | |
| Two Seas Capital LP | 3.201.962 | 2.866.962 | 335.000 | 79.536.736 | Aufgestockt | +11,7% | |
| JENNISON ASSOCIATES LLC | 3.196.705 | 700.464 | 2.496.241 | 79.406.150 | Aufgestockt | +356,4% | |
| RTW INVESTMENTS, LP | 3.177.849 | 3.177.850 | -1 | 78.937.769 | Reduziert | 0,0% | |
| ADAR1 Capital Management, LLC | 2.679.010 | 2.480.968 | 198.042 | 66.546.608 | Aufgestockt | +8,0% | |
| Alpine Global Management, LLC | 2.636.925 | 2.626.692 | 10.233 | 65.501.217 | Aufgestockt | +0,4% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.092.102 | 1.857.532 | 234.570 | 51.977.423 | Aufgestockt | +12,6% | |
| Point72 Asset Management, L.P. | 2.000.000 | 0 | 2.000.000 | 50.840.000 | Neu | +100,0% | |
| Woodline Partners LP | 1.975.869 | 1.975.869 | 0 | 49.080.586 | Unverändert | 0,0% | |
| GOLDMAN SACHS GROUP INC | 1.785.107 | 1.296.008 | 489.099 | 44.342.057 | Aufgestockt | +37,7% | |
| PERCEPTIVE ADVISORS LLC | 1.597.383 | 1.994.890 | -397.507 | 39.678.994 | Reduziert | -19,9% | |
| FARALLON CAPITAL MANAGEMENT LLC | 1.546.000 | 0 | 1.546.000 | 38.402.640 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.218.107 | 546.117 | 671.990 | 30.257.778 | Aufgestockt | +123,0% | |
| Aberdeen Group plc | 1.160.762 | 1.184.122 | -23.360 | 28.833.328 | Reduziert | -2,0% | |
| Logos Global Management LP | 1.075.000 | 1.375.000 | -300.000 | 26.703.000 | Reduziert | -21,8% | |
| BANK OF AMERICA CORP /DE/ | 893.678 | 313.481 | 580.197 | 22.198.961 | Aufgestockt | +185,1% | |
| STEMPOINT CAPITAL LP | 846.494 | 644.959 | 201.535 | 18.797.911 | Aufgestockt | +31,2% | |
| UBS Group AG | 684.551 | 732.386 | -47.835 | 17.004.246 | Reduziert | -6,5% | |
| Candriam S.C.A. | 680.372 | 680.372 | 0 | 16.900.440 | Unverändert | 0,0% | |
| NORTHERN TRUST CORP | 672.774 | 566.148 | 106.626 | 16.711.707 | Aufgestockt | +18,8% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 660.438 | 642.974 | 17.464 | 16.405.280 | Aufgestockt | +2,7% | |
| GREAT POINT PARTNERS LLC | 545.625 | 750.000 | -204.375 | 13.553.325 | Reduziert | -27,3% | |
| Connor, Clark & Lunn Investment Management Ltd. | 503.673 | 467.469 | 36.204 | 12.511.237 | Aufgestockt | +7,7% | |
| Pictet Asset Management Holding SA | 472.381 | 380.842 | 91.539 | 11.733.944 | Aufgestockt | +24,0% | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 414.236 | 0 | 414.236 | 10.289.622 | Neu | +100,0% | |
| Trails Edge Capital Partners, LP | 414.054 | 240.165 | 173.889 | 10.285.102 | Aufgestockt | +72,4% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 413.000 | 863.000 | -450.000 | 10.258.920 | Reduziert | -52,1% | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 357.606 | 288.677 | 68.929 | 8.882.933 | Aufgestockt | +23,9% | |
| BNP PARIBAS FINANCIAL MARKETS | 334.557 | 353.056 | -18.499 | 8.310.396 | Reduziert | -5,2% | |
| Granahan Investment Management, LLC | 244.430 | 230.188 | 14.242 | 6.071.641 | Aufgestockt | +6,2% | |
| Nuveen, LLC | 241.195 | 226.489 | 14.706 | 5.991.284 | Aufgestockt | +6,5% | |
| Soleus Capital Management, L.P. | 230.000 | 1.110.000 | -880.000 | 5.713.200 | Reduziert | -79,3% | |
| HighVista Strategies LLC | 225.139 | 221.883 | 3.256 | 5.592.453 | Aufgestockt | +1,5% | |
| Tetragon Partners GP Ltd | 218.507 | 166.187 | 52.320 | 5.427.714 | Aufgestockt | +31,5% | |
| CITADEL ADVISORS LLC | 217.298 | 310.507 | -93.209 | 5.397.682 | Reduziert | -30,0% | |
| Assenagon Asset Management S.A. | 205.219 | 205.219 | 0 | 5.097.640 | Unverändert | 0,0% | |
| XTX Topco Ltd | 203.029 | 33.122 | 169.907 | 5.043.240 | Aufgestockt | +513,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 192.500 | 0 | 192.500 | 4.781.700 | Neu | +100,0% | |
| PLATINUM INVESTMENT MANAGEMENT LTD | 181.774 | 181.774 | 0 | 4.515.266 | Unverändert | 0,0% | |
| MILLENNIUM MANAGEMENT LLC | 172.496 | 0 | 172.496 | 4.384.848 | Neu | +100,0% | |
| Prosight Management, LP | 175.825 | 243.404 | -67.579 | 4.367.493 | Reduziert | -27,8% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| FMR LLC | 16.947.888 | 16.990.754 | -0,3% | 420.985.547 | 16,22 |
| Deep Track Capital, LP | 11.526.971 | 11.526.971 | 0,0% | 286.329.960 | 11,03 |
| BlackRock, Inc. | 6.574.497 | 6.058.216 | +8,5% | 163.310.512 | 6,29 |
| ARMISTICE CAPITAL, LLC | 5.464.916 | 6.497.155 | -15,9% | 135.748.513 | 5,23 |
| BAKER BROS. ADVISORS LP | 5.457.881 | 5.457.881 | 0,0% | 135.573.764 | 5,22 |
| STATE STREET CORP | 4.537.929 | 3.786.926 | +19,8% | 112.722.156 | 4,34 |
| TCG Crossover Management, LLC | 4.457.988 | 1.660.933 | +168,4% | 110.736.422 | 4,27 |
| MORGAN STANLEY | 3.876.877 | 4.846.385 | -20,0% | 96.301.649 | 3,71 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.620.050 | 0 | +100,0% | 89.922.042 | 3,47 |
| Two Seas Capital LP | 3.201.962 | 2.866.962 | +11,7% | 79.536.736 | 3,06 |
| JENNISON ASSOCIATES LLC | 3.196.705 | 700.464 | +356,4% | 79.406.150 | 3,06 |
| RTW INVESTMENTS, LP | 3.177.849 | 3.177.850 | 0,0% | 78.937.769 | 3,04 |
| ADAR1 Capital Management, LLC | 2.679.010 | 2.480.968 | +8,0% | 66.546.608 | 2,56 |
| Alpine Global Management, LLC | 2.636.925 | 2.626.692 | +0,4% | 65.501.217 | 2,52 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.092.102 | 1.857.532 | +12,6% | 51.977.423 | 2,00 |
| Woodline Partners LP | 1.975.869 | 1.975.869 | 0,0% | 49.080.586 | 1,89 |
| GOLDMAN SACHS GROUP INC | 1.785.107 | 1.296.008 | +37,7% | 44.342.057 | 1,71 |
| PERCEPTIVE ADVISORS LLC | 1.597.383 | 1.994.890 | -19,9% | 39.678.994 | 1,53 |
| FARALLON CAPITAL MANAGEMENT LLC | 1.546.000 | 0 | +100,0% | 38.402.640 | 1,48 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.218.107 | 546.117 | +123,0% | 30.257.778 | 1,17 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 216 | 121,4 | 2.903 |
| 31.12.2025 | ✓ | 198 | 122,5 | 4.965 |
| 30.09.2025 | ✓ | 187 | 102,5 | 1.562 |
| 30.06.2025 | ✓ | 171 | 97,7 | 1.437 |
| 31.03.2025 | ✓ | 195 | 105,4 | 1.678 |
| 31.12.2024 | ✓ | 187 | 90,0 | 2.055 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| RTW INVESTMENTS, LP | 3.177.850 | 80.780.947 |
| TCG Crossover Management, LLC | 1.660.933 | 42.220.917 |
| Soleus Capital Management, L.P. | 1.110.000 | 28.216.200 |
| JENNISON ASSOCIATES LLC | 700.464 | 17.805.795 |
| Candriam S.C.A. | 680.372 | 17.295.793 |
| Trails Edge Capital Partners, LP | 240.165 | 6.104.994 |
| ExodusPoint Capital Management, LP | 126.621 | 3.218.706 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 122.100 | 3.104.000 |
| Trexquant Investment LP | 114.995 | 2.923.173 |
| TUDOR INVESTMENT CORP ET AL | 84.600 | 2.150.532 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| MORGAN STANLEY | 4.846.385 | 2.887.359 | +147.4 % | 123.195.151 |
| FMR LLC | 16.990.754 | 2.261.199 | +15.4 % | 431.904.967 |
| Deep Track Capital, LP | 11.526.971 | 1.798.126 | +18.5 % | 293.015.603 |
| Logos Global Management LP | 1.375.000 | 1.100.000 | +400.0 % | 34.952.500 |
| VANGUARD GROUP INC | 7.779.314 | 952.504 | +14.0 % | 197.750.162 |
| STATE STREET CORP | 3.786.926 | 894.308 | +30.9 % | 96.263.659 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 893.056 | 688.472 | +336.5 % | 22.703 |
| ARMISTICE CAPITAL, LLC | 6.497.155 | 661.155 | +11.3 % | 165.157.680 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 863.000 | 519.400 | +151.2 % | 21.937.460 |
| Woodline Partners LP | 1.975.869 | 477.144 | +31.8 % | 50.226.590 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 2.000.000 | -1.442.078 | -41.9 % | 50.840.000 |
| STEMPOINT CAPITAL LP | 644.959 | -1.194.621 | -64.9 % | 16.394.858 |
| CITADEL ADVISORS LLC | 310.507 | -600.246 | -65.9 % | 7.893.088 |
| Prosight Management, LP | 243.404 | -455.068 | -65.2 % | 6.187.330 |
| CANADA PENSION PLAN INVESTMENT BOARD | 5.200 | -409.600 | -98.7 % | 132.184 |
| Caption Management, LLC | 16.000 | -346.500 | -95.6 % | 406.720 |
| BNP PARIBAS FINANCIAL MARKETS | 353.056 | -330.346 | -48.3 % | 8.974.684 |
| JANE STREET GROUP, LLC | 159.100 | -329.166 | -67.4 % | 4.044.322 |
| Pictet Asset Management Holding SA | 380.842 | -295.735 | -43.7 % | 9.681.004 |
| CITIGROUP INC | 22.885 | -219.137 | -90.5 % | 581.737 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 12.12.2025 | Roivant Sciences Ltd. | Aktivist (13D/A) | 55,90 % | 113.327.007 | -1,00 pp | Item 4 is hereby amended by adding the following to the end thereof: Roivant purchase… |
| 05.11.2025 | FMR LLC | Passiv (13G/A) | 8,40 % | 14.729.555 | -1,70 pp | |
| 05.11.2025 | Abigail P. Johnson | Passiv (13G/A) | 8,40 % | 14.729.555 | -1,70 pp | |
| 21.04.2025 | Roivant Sciences Ltd. | Aktivist (13D/A) | 56,90 % | 96.660.341 | 0,00 pp | Item 4 is hereby amended by adding the following to the end thereof: On April 21, 202… |
| 26.03.2025 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G) | 5,59 % | 9.500.000 | +4,90 pp | |
| 26.03.2025 | David Kroin | Passiv (13G) | 5,59 % | 9.500.000 | +4,90 pp | |
| 26.03.2025 | Deep Track Capital, LP | Passiv (13G) | 5,59 % | 9.500.000 | +4,90 pp | |
| 07.03.2025 | Abigail P. Johnson | Passiv (13G/A) | 10,10 % | 17.078.093 | Neu | |
| 07.03.2025 | FMR LLC | Passiv (13G/A) | 10,10 % | 17.078.093 | Neu | |
| 15.01.2025 | Roivant Sciences Ltd. | Aktivist (13D/A) | 56,90 % | 96.660.341 | +1,60 pp | Item 4 is hereby amended by adding the following to the end thereof: Roivant purchase… |
| 14.02.2024 | David Kroin | Passiv (13G/A) | 0,69 % | 1.000.000 | -6,83 pp | |
| 14.02.2024 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G/A) | 0,69 % | 1.000.000 | -6,83 pp | |
| 14.02.2024 | Deep Track Capital, LP | Passiv (13G/A) | 0,69 % | 1.000.000 | -6,83 pp | |
| 04.10.2023 | Roivant Sciences Ltd. | Aktivist (13D/A) | 55,30 % | 79.815.331 | -8,50 pp | |
| 14.02.2023 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G/A) | 7,52 % | 9.710.000 | +1,69 pp | |
| 14.02.2023 | Deep Track Capital, LP | Passiv (13G/A) | 7,52 % | 9.710.000 | +1,69 pp | |
| 14.02.2023 | David Kroin | Passiv (13G/A) | 7,52 % | 9.710.000 | +1,69 pp | |
| 05.12.2022 | RTW Investments, LP | Passiv (13G/A) | Ausstieg | 0 | -5,87 pp | |
| 05.12.2022 | Roderick Wong | Passiv (13G/A) | Ausstieg | 0 | -6,54 pp | |
| 05.12.2022 | RTW Master Fund, Ltd. | Passiv (13G/A) | Ausstieg | 0 | -4,10 pp | |
| 02.12.2022 | Roderick Wong | Passiv (13G/A) | 6,54 % | 8.459.241 | Neu | |
| 02.12.2022 | RTW Investments, LP | Passiv (13G/A) | 5,87 % | 7.592.253 | Neu | |
| 02.12.2022 | RTW Master Fund, Ltd. | Passiv (13G/A) | 4,10 % | 5.300.729 | Neu | |
| 11.02.2022 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G) | 5,83 % | 6.780.827 | Neu | |
| 11.02.2022 | Deep Track Capital, LP | Passiv (13G) | 5,83 % | 6.780.827 | Neu | |
| 11.02.2022 | David Kroin | Passiv (13G) | 5,83 % | 6.780.827 | Neu | |
| 02.08.2021 | Roivant Sciences Ltd. | Aktivist (13D/A) | 63,80 % | 73.398.664 | +6,30 pp |
Stammdaten
Immunovant, Inc. ist ein Biopharmaunternehmen in der klinischen Phase, das monoklonale Antikörper zur Behandlung von Autoimmunerkrankungen entwickelt. Es entwickelt Batoclimab, einen neuartigen vollständig humanen monoklonalen Antikörper, der selektiv an den neonatalen Fc-Rezeptor (Fragment Crystallizable Receptor) bindet und diesen hemmt. Das Mittel befindet sich in Phase-IIa-Kliniktests zur Behandlung von Myasthenia gravis und Augenkrankheit der Schilddrüse sowie hat die Einleitung von Phase-II-Kliniktests zur Behandlung von Warm-Autoimmunhämolytischer Anämie abgeschlossen. Das Unternehmen wurde 2018 gegründet und hat seinen Sitz in New York, New York. Immunovant, Inc. ist eine Tochtergesellschaft von Roivant Sciences Ltd.
Unternehmen & Branche
| Name | Immunovant, Inc. |
|---|---|
| Ticker | IMVT |
| CIK | 0001764013 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 45258J102 |
|---|---|
| ISIN | US45258J1025 |
| Typ | Common Stock |
| Marktkapitalisierung | 6,71 Mrd. USD |
| Beta | 0,72 |
Bewertung
| KBV (P/B) | 7,86 vs. 1,37 (2022) ▲ |
|---|---|
| FCF-Rendite | -6,1 % vs. -16,6 % (2022) ▲ |
Qualität & Bilanz
| ROIC | -59,3 % vs. -33,2 % (2022) ▼ |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.03.2026, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2022. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2022 | 2023 | 2024 | 2025 | 2026 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 1,37 | 5,58 | 7,61 | 4,11 | 5,94 | |
| FCF-Rendite | -16,6 % | -9,3 % | -4,6 % | -13,0 % | -8,0 % | |
| Qualität & Bilanz | ||||||
| ROIC | -33,2 % | -58,0 % | -42,0 % | -58,5 % | -59,3 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-K | -505.606.000 | -2,77 | 957.014.000 | 852.592.000 | |
| 2025-12-31 | 10-Q | -110.635.000 | -0,61 | 1.052.392.000 | 986.135.000 | |
| 2025-09-30 | 10-Q | -126.502.000 | -0,73 | 582.959.000 | 519.705.000 | |
| 2025-06-30 | 10-Q | -120.613.000 | -0,71 | 661.440.000 | 608.540.000 | |
| 2025-03-31 | 10-K | -413.840.000 | -2,73 | 776.222.000 | 707.447.000 | |
| 2024-12-31 | 10-Q | -111.122.000 | -0,76 | 420.932.000 | 352.617.000 | |
| 2024-09-30 | 10-Q | -109.119.000 | -0,74 | 515.707.000 | 449.054.000 | |
| 2024-06-30 | 10-Q | -87.150.000 | -0,60 | 589.678.000 | 544.660.000 | |
| 2024-03-31 | 10-K | -259.336.000 | -1,88 | 666.365.000 | 617.757.000 | |
| 2023-12-31 | 10-Q | -51.418.000 | -0,36 | 711.446.000 | 679.344.000 | |
| 2023-09-30 | 10-Q | -58.662.000 | -0,45 | 292.070.000 | 251.811.000 | |
| 2023-06-30 | 10-Q | -73.937.000 | -0,57 | 351.222.000 | 299.865.000 | |
| 2023-03-31 | 10-K | -210.960.000 | -1,71 | 405.838.000 | 362.494.000 | |
| 2022-12-31 | 10-Q | -63.227.000 | -0,49 | 456.243.000 | 414.678.000 | |
| 2022-09-30 | 10-Q | -47.928.000 | -0,41 | 428.146.000 | 395.748.000 | |
| 2022-06-30 | 10-Q | -40.373.000 | -0,35 | 458.656.000 | 436.493.000 | |
| 2022-03-31 | 10-K | -156.730.000 | -1,43 | 515.564.000 | 469.825.000 | |
| 2021-12-31 | 10-Q | -41.385.000 | -0,36 | 543.182.000 | 505.148.000 | |
| 2021-09-30 | 10-Q | -37.703.000 | -0,35 | 566.732.000 | 536.397.000 | |
| 2021-06-30 | 10-Q | -30.471.000 | -0,31 | 388.027.000 | 365.532.000 |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q3 2025 | 31.12.2025 | 06.02.2026 | – | -0,61 |
| Q2 2025 | 30.09.2025 | 06.02.2026 | – | -0,73 |
| Q1 2025 | 30.06.2025 | 06.02.2026 | – | -0,71 |
| Q3 2024 | 31.12.2024 | 06.02.2026 | – | -0,76 |
| Q2 2024 | 30.09.2024 | 06.02.2026 | – | -0,74 |
| Q1 2024 | 30.06.2024 | 06.02.2026 | – | -0,60 |
| Q3 2023 | 31.12.2023 | 06.02.2025 | – | -0,36 |
| Q2 2023 | 30.09.2023 | 06.02.2025 | – | -0,45 |
| Q1 2023 | 30.06.2023 | 06.02.2025 | – | -0,57 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 20.05.2026 | 10-K | 31.03.2026 | 50 Tage | SEC » |
| 06.02.2026 | 10-Q | 31.12.2025 | 37 Tage | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 11.08.2025 | 10-Q | 30.06.2025 | 42 Tage | SEC » |
| 29.05.2025 | 10-K | 31.03.2025 | 59 Tage | SEC » |
| 06.02.2025 | 10-Q | 31.12.2024 | 37 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 06.08.2024 | 10-Q | 30.06.2024 | 37 Tage | SEC » |
| 29.05.2024 | 10-K | 31.03.2024 | 59 Tage | SEC » |
| 12.02.2024 | 10-Q | 31.12.2023 | 43 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 10.08.2023 | 10-Q | 30.06.2023 | 41 Tage | SEC » |
| 22.05.2023 | 10-K | 31.03.2023 | 52 Tage | SEC » |
| 03.02.2023 | 10-Q | 31.12.2022 | 34 Tage | SEC » |
| 04.11.2022 | 10-Q | 30.09.2022 | 35 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 08.06.2022 | 10-K | 31.03.2022 | 69 Tage | SEC » |
| 04.02.2022 | 10-Q | 31.12.2021 | 35 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 09.08.2021 | 10-Q | 30.06.2021 | 40 Tage | SEC » |
| 01.06.2021 | 10-K | 31.03.2021 | 62 Tage | SEC » |
| 16.02.2021 | 10-Q | 31.12.2020 | 47 Tage | SEC » |
| 12.11.2020 | 10-Q | 30.09.2020 | 43 Tage | SEC » |
| 12.08.2020 | 10-Q | 30.06.2020 | 43 Tage | SEC » |
| 29.06.2020 | 10-K | 31.03.2020 | 90 Tage | SEC » |
Filing-Analyse (10-K / 10-Q)
Narrative-Analyse der letzten Quartals-/Jahresberichte durch Claude (nur Coverage-Gruppen-Mitglieder). Keine Anlageberatung — der qualitative Score dient der Einordnung, nicht als Kaufempfehlung; siehe allgemeiner Hinweis am Seitenende.
| Datum | Form | Stimmung | Guidance | Qualitativ | Zusammenfassung | |
|---|---|---|---|---|---|---|
| 06.02.2026 | 10-Q | 0,20 | ↑ | 58,0 | Immunovant verzeichnet solide Fortschritte bei IMVT-1402 mit laufenden, potenziell registrierungsfähigen Studien in sechs Indikationen und e… | |
|
Zusammenfassung: Immunovant verzeichnet solide Fortschritte bei IMVT-1402 mit laufenden, potenziell registrierungsfähigen Studien in sechs Indikationen und einer starken Liquiditätsposition von $994,5 Mio. nach der Kapitalerhöhung im Dezember 2025, die nach Unternehmensangaben bis zum potenziellen kommerziellen Launch in der Graves-Erkrankung reichen soll. Für die zweite Hälfte des Kalenderjahres 2026 werden Top-Line-Daten aus den Phase-3-TED-Studien (batoclimab, H1 2026), der vollständig enrollten D2T-RA-Studie sowie der CLE-Studie erwartet. Neu hinzugekommen sind ein erhöhtes Streitrisiko mit dem Lizenzgeber HanAll bezüglich der Rückgabe von batoclimab-Rechten sowie steuerliche Risiken aus einer internen IP-Umstrukturierung im Januar 2026. Die operativen Verluste stiegen im Neun-Monatszeitraum auf $357,8 Mio. an; das Unternehmen erzielt weiterhin keinen Umsatz. Guidance-Zitate:
Risiko-Änderungen:
|
||||||
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 29.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 15.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 02.08.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 13.07.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-01 | 14.027 | 27,15 | 380.833 |
| 2026-04-07 | 218 | 24,89 | 5.426 |
| 2026-04-06 | 259 | 24,50 | 6.346 |
| 2026-03-24 | 139 | 24,38 | 3.389 |
| 2026-03-23 | 622 | 22,98 | 14.294 |
| 2026-03-20 | 2.211 | 23,65 | 52.290 |
| 2026-03-16 | 589 | 24,41 | 14.377 |
| 2026-03-13 | 73 | 24,99 | 1.824 |
| 2026-03-12 | 95 | 25,56 | 2.428 |
| 2026-03-11 | 3.999 | 25,72 | 102.854 |
| 2026-03-10 | 8.472 | 26,41 | 223.746 |
| 2026-03-05 | 270 | 27,08 | 7.312 |
| 2026-02-24 | 1.786 | 27,20 | 48.579 |
| 2026-02-23 | 1.934 | 26,60 | 51.444 |
| 2026-02-06 | 43.587 | 24,06 | 1.048.703 |
| 2026-02-04 | 82 | 25,80 | 2.116 |
| 2026-01-20 | 23.491 | 26,27 | 617.109 |
| 2026-01-14 | 27.434 | 26,18 | 718.222 |
| 2026-01-12 | 3.053 | 26,03 | 79.470 |
| 2025-12-30 | 4.078 | 25,61 | 104.438 |
| 2025-12-26 | 38 | 26,88 | 1.021 |
| 2025-12-23 | 5.286 | 27,54 | 145.576 |
| 2025-12-22 | 17.351 | 26,68 | 462.925 |
| 2025-12-19 | 1.824 | 26,18 | 47.752 |
| 2025-12-18 | 109.909 | 26,98 | 2.965.345 |
| 2025-12-17 | 181 | 26,61 | 4.816 |